

## CURRICULUM VITAE

### **EZIO GIACOBINI, MD, PhD**

ADJUNCT PROFESSOR OF PHARMACOLOGY,  
PSYCHIATRY AND NEUROLOGY

SOUTHERN ILLINOIS UNIVERSITY  
- SPRINGFIELD, ILLINOIS, USA



### **EDUCATION AND PROFESSIONAL TRAINING**

- M.D. (cum laude) 1953, University of Turin, Medical School, Italy  
Ph.D. 1959, Neuropharmacology, Karolinska Institutet, Stockholm, Sweden  
Docent 1962, Docent of Pharmacology, Karolinska Institutet, Stockholm, Sweden  
1953                    Doctoral Research Fellow, Department of Pathology, Karolinska Institutet, Stockholm, Sweden  
1953-1954            Resident in Neurology, Department of Neurology, University of Stockholm, Sweden and Resident in Psychiatry, Sidsjöns Regional Mental Hospital, Sundsvall  
  
1963-1970            Associate Professor of Pharmacology, Karolinska Institutet, Medical School, Stockholm, Sw  
1970-1971            President, Research and Development, Astra Draco AB Pharmaceutical Company, Lund, Sweden  
  
1972-1983            Professor of Bio-behavioral Sciences; Chairman, Laboratory of Neuropsychopharmacology, University of Connecticut, Storrs, CT, USA  
1976-1983            Professor of Pharmacology, University of Connecticut Medical School, Health Center, Farmington, CT, USA, Joint appointment  
1983-1995            Professor and Chairman of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, USA  
1989-1994            Scientific Director, NIH Alzheimer Center, Southern Ill University School of Medicine, Springfield Ill. USA  
1984-1995            Adjunct Professor/Gerontology Program, Sangamon State University, Springfield, IL, USA  
1988- pres.            Adjunct Professor of Psychiatry, Southern Illinois University School of Medicine, Springfield, IL, USA  
1993- pres.            Adjunct Professor of Neurology, Southern Illinois University School Medicine, Springfield, IL, USA  
1995- pres.            Adjunct Professor of Pharmacology, Psychiatry and Neurology, Southern Illinois University School of Medicine, Springfield, IL USA  
1995-pres.            Medical Consultant Department of Rehabilitation and Geriatrics, University of Geneva Medical School, Geneva, Switzerland

### **CLINICAL TRAINING**

Neurology, psychiatry and clinical psychopharmacology (1953-1970) in Sweden, amounting to 7 years  
Doctor of Medicine (M.D.) (Italy), 1953 and Sweden, 1959  
M.D. Honoris Causa University of Kuopio, Finland 1998

### **FIELD OF SPECIALIZATION**

#### Basic neuroscience

Neuropharmacology and Neurochemistry of the cholinergic system

#### Clinical neuroscience

Psychiatry and Clinical Psychopharmacology

Therapy of Alzheimer Disease

### **JOURNALS**

#### Chief Editor and Founder:

Developmental Neuroscience (Karger AG Publ., Basel), 1978-1982 (with A.Vernadakis); International Journal of Developmental Neuroscience (Pergamon Press, New York), 1982-1987 (with A. Vernadakis, Chief Editor, 1997-2005, Alzheimer Insights, European Editor; Japanese J. of Pharmacology 1997-2005. Member Editorial Board: Journal of

Neuropharmacology; International Journal of Developmental Neuroscience; Journal of Neuroscience Research, Neurochemical Research; Neurobiology of Aging, CNS Drugs, Current Alzheimer Research, Alzheimer Research and Assoc. Disorders, Journal of Alzheimer Research

## **GRANT SUPPORT**

### ***In USA***

- A) Principal investigator: NIH grants during the period 1973-1989
  - Chemistry and Pharmacology of Developing Sympathetic Ganglia, USPH, NS-11496
  - Chemistry and Function of Piperidine in the CNS, USPH, NS-11430
  - Localization and Metabolism of Pipecolic Acid in CNS, USPH, NS-15086
  - Aging of the Brain and Dementia, USPH, AG-05416 (December 1985-November 1989)
- B) Illinois Department of Public Health (19 grants) (1989- present)
- C) National Institute of Aging Alzheimer Disease Center Core Grant #P30AG08014 (1991-1992)
- D) National Institutes of Aging: "A Biopsy Study of Alzheimer Neurochemistry" #P30AG08014 (1990-1991)
- E) National Institute of Aging: "In Vivo Effects of Cholinesterase inhibitors in Rat CNS" #P30AG08014 (1991-1993)

### ***In Switzerland***

- Co-Investigator: Swiss National Research Foundation, PROJECT NRP 38 Nr 44074 (1996-1991)  
Brain energy metabolism in dementias
- Co-Investigator SHCS Project (2006-2007) Cognitive disorders in HIV infection.
- Co-investigator SPUM Project 33CM30-124111 ( Progr.Spec.Med. Univ. 2009-2011)  
Conversion of mild cognitive impairment to Alzheimer's Disease.CHF 3.155.174.00

## **List of publications (2000-2008)**

1. Giacobini E, Becker RE: One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? J Alzheimer's Dis. 2007 12 (1):37-52 (Review).
2. Giacobini E: Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18(Suppl 1): S1-5.
3. Giacobini E: Cholinesterases: New roles in brain function and in Alzheimer's disease. Neurochem Res 2003; 28(3-4): 515-22.
4. Giacobini E: Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004; 50(4): 433-40.
5. Giacobini E: Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease. J Neural Transm Suppl 2002(62): 181-7.
6. Giacobini E; Spiegel R, Enz A, Veroff AE, Cutler NR: Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002; 109(7-8): 1053-65.
7. Giacobini E: Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging 2001; 18(12): 891-8.
8. Giacobini E: Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs 2001; 15(2): 85-91.
9. Giacobini E: Is anti-cholinesterase therapy of Alzheimer's disease delaying progression? Aging (Milano) 2001; 13(3): 247-54.
10. Giacobini E: Cholinesterase inhibitors stabilize Alzheimer's disease. Ann N Y Acad Sci 2000; 920: 321-7.
11. Giacobini E: Cholinesterase inhibitors stabilize Alzheimer disease. Neurochem Res 2000; 25(9-10): 1185-90.
12. Becker RE, Greig NH, Giacobini E : Why so many drugs for Alzheimer's Disease fail in development ? Time for new methods and new practices ? J. Alz.Dis.2008 ;15(2) :303-325
13. Martinez A, Lahiri D.K, Giacobini E and Greig N.H :Advances in Alzheimer Therapy :understanding pharmacological approaches to the disease. Current Alzheimer Research 2009;6(2): 83-86
14. Simioni S, Cavassini M, Annoni J-m, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave J-P, Giacobini E, Hirschel B and Du Pasquier R, Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 1243-1250

### **Recent BOOKS (Editor and Chapter Author)**

1. Cholinesterase and Cholinesterase Inhibitors. Martin Dunitz Publ. 2000
2. Butyrylcholinesterase Its Function and Inhibitors. Martin Dunitz-Taylor-Francis Publ. 2003
3. The Brain Cholinergic System in Health and Disease (with G.Pepeu) Informa Health Care 2006

**Total PUBLICATIONS (1953 -2009) : 290 including Book Chapters**